KR102917671B1 - Il-13 수용체 알파 2 표적화된 제타카인 지정 t 세포 면역요법 - Google Patents

Il-13 수용체 알파 2 표적화된 제타카인 지정 t 세포 면역요법

Info

Publication number
KR102917671B1
KR102917671B1 KR1020207028968A KR20207028968A KR102917671B1 KR 102917671 B1 KR102917671 B1 KR 102917671B1 KR 1020207028968 A KR1020207028968 A KR 1020207028968A KR 20207028968 A KR20207028968 A KR 20207028968A KR 102917671 B1 KR102917671 B1 KR 102917671B1
Authority
KR
South Korea
Prior art keywords
cell
nucleic acid
cells
alternatives
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207028968A
Other languages
English (en)
Korean (ko)
Other versions
KR20200131851A (ko
Inventor
지아코모 탬펠라
마이클 씨. 젠센
아담 존슨
Original Assignee
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 filed Critical 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트
Priority to KR1020267001996A priority Critical patent/KR20260021083A/ko
Publication of KR20200131851A publication Critical patent/KR20200131851A/ko
Application granted granted Critical
Publication of KR102917671B1 publication Critical patent/KR102917671B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
KR1020207028968A 2018-03-14 2019-03-12 Il-13 수용체 알파 2 표적화된 제타카인 지정 t 세포 면역요법 Active KR102917671B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267001996A KR20260021083A (ko) 2018-03-14 2019-03-12 Il-13 수용체 알파 2 표적화된 제타카인 지정 t 세포 면역요법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643139P 2018-03-14 2018-03-14
US62/643,139 2018-03-14
PCT/US2019/021833 WO2019178085A1 (en) 2018-03-14 2019-03-12 Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267001996A Division KR20260021083A (ko) 2018-03-14 2019-03-12 Il-13 수용체 알파 2 표적화된 제타카인 지정 t 세포 면역요법

Publications (2)

Publication Number Publication Date
KR20200131851A KR20200131851A (ko) 2020-11-24
KR102917671B1 true KR102917671B1 (ko) 2026-01-27

Family

ID=67907266

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207028968A Active KR102917671B1 (ko) 2018-03-14 2019-03-12 Il-13 수용체 알파 2 표적화된 제타카인 지정 t 세포 면역요법
KR1020267001996A Pending KR20260021083A (ko) 2018-03-14 2019-03-12 Il-13 수용체 알파 2 표적화된 제타카인 지정 t 세포 면역요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267001996A Pending KR20260021083A (ko) 2018-03-14 2019-03-12 Il-13 수용체 알파 2 표적화된 제타카인 지정 t 세포 면역요법

Country Status (13)

Country Link
US (1) US12606603B2 (https=)
EP (2) EP4491718A3 (https=)
JP (2) JP7314161B2 (https=)
KR (2) KR102917671B1 (https=)
CN (1) CN112088165A (https=)
AU (2) AU2019234580B2 (https=)
BR (1) BR112020018534A2 (https=)
CA (1) CA3093791A1 (https=)
EA (1) EA202091984A1 (https=)
IL (1) IL277268A (https=)
MX (2) MX2020009464A (https=)
SG (1) SG11202008926RA (https=)
WO (1) WO2019178085A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765041A4 (en) 2018-03-14 2021-12-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY
EP4577575A1 (en) * 2022-08-25 2025-07-02 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090257994A1 (en) * 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
BRPI0819598A2 (pt) 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
KR101763499B1 (ko) 2012-11-07 2017-07-31 화이자 인코포레이티드 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체
US9758807B2 (en) 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
BR112017005631A2 (pt) 2014-09-19 2018-06-26 City Of Hope células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
CA2992989A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
WO2017040930A2 (en) * 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
IL287889B2 (en) * 2016-02-05 2024-03-01 Hope City Administration of engineered t cells for treatment of cancers in the central nervous system
KR20230148844A (ko) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
US12304935B2 (en) * 2016-07-29 2025-05-20 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
AU2017319702B2 (en) 2016-09-02 2024-11-14 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US12083148B2 (en) 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
EP3765041A4 (en) 2018-03-14 2021-12-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clinical Cancer Research, Vol.21(18), pp. 4062-4072 (2015.09.15.)
Molecular Therapy, Vol.26(1), pp.31-44 (2017.10.05.)*

Also Published As

Publication number Publication date
BR112020018534A2 (pt) 2020-12-29
MX2020009464A (es) 2021-01-15
EP3765487A1 (en) 2021-01-20
CN112088165A (zh) 2020-12-15
SG11202008926RA (en) 2020-10-29
AU2019234580A1 (en) 2020-10-08
JP2021518111A (ja) 2021-08-02
JP2023134631A (ja) 2023-09-27
US12606603B2 (en) 2026-04-21
US20210017246A1 (en) 2021-01-21
WO2019178085A1 (en) 2019-09-19
CA3093791A1 (en) 2019-09-19
KR20200131851A (ko) 2020-11-24
EA202091984A1 (ru) 2021-02-18
EP4491718A2 (en) 2025-01-15
IL277268A (en) 2020-10-29
EP3765487A4 (en) 2022-01-05
JP7696958B2 (ja) 2025-06-23
EP4491718A3 (en) 2025-03-26
MX2025010440A (es) 2025-10-01
AU2019234580B2 (en) 2024-02-01
JP7314161B2 (ja) 2023-07-25
AU2024202681A1 (en) 2024-05-16
KR20260021083A (ko) 2026-02-12

Similar Documents

Publication Publication Date Title
JP6788573B2 (ja) メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
TWI790213B (zh) 用於使用融合蛋白之tcr重編程的組合物及方法
KR102614675B1 (ko) 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
AU2015374296B2 (en) Methods of making chimeric antigen receptor-expressing cells
US20220168389A1 (en) Methods of making chimeric antigen receptor-expressing cells
US20200370012A1 (en) Methods of making chimeric antigen receptor-expressing cells
WO2018026819A2 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
TW201920250A (zh) 用於以基因方式修飾且擴展淋巴球以及調節其活性之方法及組合物
KR20240001720A (ko) Fc-엡실론 car
Chambers et al. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors
AU2019215031A1 (en) Combination therapy using a chimeric antigen receptor
AU2024202681A1 (en) IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy
KR20200110326A (ko) Daric 인터류킨 수용체
WO2025194140A1 (en) Thermally controlled gene expression and uses thereof
WO2026006767A1 (en) Tethered il-9/il-9r and related engineered cells and methods
TW202307210A (zh) Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0102 Application to register extension of term of patent right following delayed registration

St.27 status event code: A-4-4-G10-G15-tad-PA0102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 134